MedTrace Logo

A Proof-of-Concept Study Assessing NEO6860 in Osteoarthritis Pain

NCT02712957 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-03-13

No results posted yet for this study

Summary

The purpose of this study is to assess NEO6860, a modality selective TRPV1 antagonist, in patients with pain associated with osteoarthritis of the knee.

Conditions

  • Pain
  • Osteoarthritis of the Knee

Interventions

DRUG

NEO6860

TRPV1 antagonist

DRUG

NEO6860 placebo

Inactive substance

DRUG

Naproxen

NSAID

DRUG

Naproxen placebo

inactive substance

Sponsors & Collaborators

  • Neomed Institute

    lead OTHER

Principal Investigators

  • Dan A Chiche, MD · Neomed Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-11-17
Completion
2016-11-24

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02712957 on ClinicalTrials.gov